Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Improving evidence developed from population-level experience with targeted agents.

McClellan MB, Daniel GW, Dickson D, Perlmutter J, Berger DP, Miller V, Nussbaum S, Malin J, Romine MH, Schilsky RL.

Clin Pharmacol Ther. 2015 May;97(5):478-87. doi: 10.1002/cpt.90. Epub 2015 Apr 3. Review.

PMID:
25676878
2.

[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].

Ludwig WD.

Z Evid Fortbild Qual Gesundhwes. 2012;106(1):11-22. doi: 10.1016/j.zefq.2011.12.001. Epub 2012 Jan 10. Review. German.

PMID:
22325103
3.

Oncology trial design: More accurately and efficiently advancing the field.

Hohl RJ.

Clin Pharmacol Ther. 2015 May;97(5):430-2. doi: 10.1002/cpt.94. No abstract available.

PMID:
25684240
4.

The role of nonrandomized trials in the evaluation of oncology drugs.

Simon R, Blumenthal GM, Rothenberg ML, Sommer J, Roberts SA, Armstrong DK, LaVange LM, Pazdur R.

Clin Pharmacol Ther. 2015 May;97(5):502-7. doi: 10.1002/cpt.86. Epub 2015 Apr 7.

PMID:
25676488
5.

The changing face of percutaneous image-guided biopsy: molecular profiling and genomic analysis in current practice.

Marshall D, Laberge JM, Firetag B, Miller T, Kerlan RK.

J Vasc Interv Radiol. 2013 Aug;24(8):1094-103. doi: 10.1016/j.jvir.2013.04.027. Epub 2013 Jun 24. Review.

PMID:
23806383
6.

Biology-driven phase II trials: what is the optimal model for molecular selection?

Andre F, Delaloge S, Soria JC.

J Clin Oncol. 2011 Apr 1;29(10):1236-8. doi: 10.1200/JCO.2010.31.6877. Epub 2011 Feb 22. No abstract available.

PMID:
21343554
7.

Personalizing oncology: perspectives and prospects.

Mendelsohn J.

J Clin Oncol. 2013 May 20;31(15):1904-11. doi: 10.1200/JCO.2012.45.3605. Epub 2013 Apr 15. Review.

PMID:
23589547
8.

Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.

Vela CM, Knepper TC, Gillis NK, Walko CM, McLeod HL, Hicks JK.

Pharmacotherapy. 2017 Sep;37(9):1043-1051. doi: 10.1002/phar.1917. Epub 2017 Apr 2.

PMID:
28235141
9.

Personalized oncology: recent advances and future challenges.

Kalia M.

Metabolism. 2013 Jan;62 Suppl 1:S11-4. doi: 10.1016/j.metabol.2012.08.016. Epub 2012 Sep 19. Review.

PMID:
22999010
10.

Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.

Lerose R, Musto P, Aieta M, Papa C, Tartarone A.

Eur J Clin Pharmacol. 2012 May;68(5):505-12. doi: 10.1007/s00228-011-1173-6. Epub 2011 Dec 14. Review.

PMID:
22166932
11.

Emerging approaches to target tumor metabolism.

Ross SJ, Critchlow SE.

Curr Opin Pharmacol. 2014 Aug;17:22-9. doi: 10.1016/j.coph.2014.07.001. Epub 2014 Jul 19. Review.

PMID:
25048629
12.

What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?

Sargent D.

Oncologist. 2010;15 Suppl 1:19-23. doi: 10.1634/theoncologist.2010-S1-19.

13.

Somatic alterations as the basis for resistance to targeted therapies.

Blair BG, Bardelli A, Park BH.

J Pathol. 2014 Jan;232(2):244-54. doi: 10.1002/path.4278. Review.

14.

The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?

Arnedos M, Vielh P, Soria JC, Andre F.

J Pathol. 2014 Jan;232(2):274-82. doi: 10.1002/path.4276. Review.

PMID:
24114621
15.

Giving Up on Precision Oncology? Not So Fast!

Warner JL.

Clin Transl Sci. 2017 May;10(3):128-129. doi: 10.1111/cts.12457. Epub 2017 Feb 21. No abstract available.

16.

New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology.

Rossig C, Juergens H, Berdel WE.

Pediatr Hematol Oncol. 2011 Oct;28(7):539-55. doi: 10.3109/08880018.2011.613094. Review.

PMID:
21936619
17.

Off-label drug use in oncology: a systematic review of literature.

Saiyed MM, Ong PS, Chew L.

J Clin Pharm Ther. 2017 Jun;42(3):251-258. doi: 10.1111/jcpt.12507. Epub 2017 Feb 5. Review.

PMID:
28164359
18.

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG.

J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919. Epub 2011 Dec 5.

PMID:
22147736
19.

Is tailored therapy feasible in oncology?

Gasparini G, Longo R, Torino F, Gattuso D, Morabito A, Toffoli G.

Crit Rev Oncol Hematol. 2006 Jan;57(1):79-101. Epub 2005 Dec 7. Review.

PMID:
16337806
20.

Improving the outcomes: developing cancer therapeutics.

Utku N.

Future Oncol. 2012 Jan;8(1):87-103. doi: 10.2217/fon.11.136. Review.

PMID:
22149037

Supplemental Content

Support Center